Results 351 to 360 of about 146,874 (392)
Some of the next articles are maybe not open access.
Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology, 2008Trastuzumab is a monoclonal antibody that targets the extracellular domain of HER2, a member of the epidermal growth factor receptor (EGFR) family. Trastuzumab is currently approved for the treatment of breast cancer overexpressing HER2, given alone or in combination with paclitaxel or docetaxel.
Luc Gigou +2 more
openaire +3 more sources
Trastuzumab for gastric cancer [PDF]
Expert Opinion on Biological Therapy, 2009 Gastric cancer is a disease with different management approaches in different regions, especially between Western and Asian countries. Surgery is the mainstay of treatment for non-metastatic disease. Perioperative chemotherapy or adjuvant radio-chemotherapy is recommended, since recurrences are common after curative resection.
Michael B. Sawyer +2 more
openaire +2 more sources
Trastuzumab Deruxtecan (Enhertu)
Canadian Journal of Health Technologies, 2022CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
European Journal of Cancer, 2010
Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade. HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or ...
Alicia Okines, David Cunningham
openaire +3 more sources
Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade. HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or ...
Alicia Okines, David Cunningham
openaire +3 more sources
Cardiotoxicity Profile of Trastuzumab
Drug Safety, 2008Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase HER2/ErbB2. This agent has shown a highly significant antitumour effect for patients with HER2-positive breast cancer, and is now considered part of the standard regimens for the treatment of this disease in both the metastatic and adjuvant ...
Michael S. Ewer, Steven M. Ewer
openaire +2 more sources
Hospital Pharmacy, 1999
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
openaire +2 more sources
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
openaire +2 more sources
Trastuzumab-Induced Cardiotoxicity
Oncology Nursing Forum, 2009To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education.Literature regarding cardiotoxicity and
Jana M. Glotzer +4 more
openaire +3 more sources
Trastuzumab-Induced Cardiomyopathy
Journal of Cardiac Failure, 2008Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. It improves survival and increases response to chemotherapy. The major side effect of trastuzumab is cardiotoxicity manifesting as a reduction in left ventricular systolic function, either asymptomatic or with signs and symptoms of heart failure.
Joseph D. Mishkin +2 more
openaire +3 more sources
Efficacy and safety of trastuzumab
Expert Opinion on Drug Safety, 2004The human epidermal growth factor receptor (HER) 2 is overexpressed in approximately 20-25% of human breast cancers and is an independent adverse prognostic factor. Targeted therapy directed against this receptor has been developed in the form of a humanised monoclonal antibody, trastuzumab.
Ian E. Smith, Robin L. Jones
openaire +3 more sources
Trastuzumab‐associated cardiotoxicity
Cancer, 2002AbstractTrastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to occur with trastuzumab when administered alone and in combination with antineoplastic agents, particularly anthracyclines.
openaire +2 more sources